Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

The Gene variant that protects against severe COVID-19

A gene variant of OAS1 has been implicated in reducing the risk of severe COVID-19 disease. This warrants developing agents/drugs that can increase the level of OAS1 enzyme, thereby reducing the severity of COVID-19.

Advanced age and comorbidities are known to be high risk factors for COVID-19. There are several studies suggesting that genetic make-up predisposes some people to severe symptoms of COVID-19, while others remain almost immune to the disease1.   

While investigating whether circulating proteins affect susceptibility and severity to COVID-19, the researchers found association of increased OAS enzyme levels with reduced COVID-19 severity or death. OAS genes encode enzymes that are induced by interferons and activate latent RNase L, resulting in degradation of intracellular double-stranded RNA, as possible antiviral mechanism. The OAS1/2/3 locus on chromosome 12 (12q24.13), of Neanderthal origin confers 23% reduced risk of patients becoming critically ill with COVID-192. While certain studies implicate increased OAS1 levels with reduced risk for COVID-19, other studies implicate increase in OAS3 levels to be associated with reduced risk. Due to the presence of numerous genetic variants in the locus, identifying the exact variant responsible is important for drug development for agents that increase OAS levels. 

In a recent meta-analysis of the OAS region of European ancestry that spans 75Kb region harbouring the OAS1, 2 and 3 genes, the investigators found a variant, rs10774671, that represents a longer, 60% more active form of OAS1 enzyme2. This variant was also found in the individuals with African ancestry suggesting that individuals of African ancestry had the same level of protection as those of European ancestry. The longer variant of the protein is found to be more effective in providing protection against SARS-CoV-2. This recent study has demonstrated that this splice variant (rs10774671) of OAS1 is likely responsible for association with reduced COVID-19 severity.2

Based on these studies, agents that increase OAS1 levels, are suggested to be prioritised for drug development3

***

Reference:  

  1. Prasad U 2021. Genetics of COVID-19: Why Some People Develop Severe Symptoms. Scientific European. Posted 6 February 2021. Available at https://www.scientificeuropean.co.uk/covid-19/genetics-of-covid-19-why-some-people-develop-severe-symptoms/  
  2. Huffman, J.E., Butler-Laporte, G., Khan, A. et al. Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. Nat Genet (2022). Published: 13 January 2022. DOI: https://doi.org/10.1038/s41588-021-00996-8 
  3. Zhou, S., Butler-Laporte, G., Nakanishi, T. et al. A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. Nat Med 27, 659–667 (2021). Published: 25 February 2021.DOI: https://doi.org/10.1038/s41591-021-01281-1 

***

Rajeev Soni
Rajeev Sonihttps://web.archive.org/web/20220523060124/https://www.rajeevsoni.org/publications/
Dr. Rajeev Soni (ORCID ID : 0000-0001-7126-5864) has a Ph.D. in Biotechnology from the University of Cambridge, UK and has 25 years of experience working across the globe in various institutes and multinationals such as The Scripps Research Institute, Novartis, Novozymes, Ranbaxy, Biocon, Biomerieux and as a principal investigator with US Naval Research Lab in drug discovery, molecular diagnostics, protein expression, biologic manufacturing and business development.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

Were Hunter-Gatherers Healthier Than the Modern Humans?

Hunter gatherers are often thought of as dumb animalistic...

Aviptadil Could Reduce Mortality Among Severely Ill COVID Patients

In June 2020, RECOVERY trial from a group of...
- Advertisement -
93,065FansLike
47,315FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe